Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Mel-Immune

Financiado

An integrative genetic approach for the exploration of melanoma immunological in...

An integrative genetic approach for the exploration of melanoma immunological interactions Immunotherapy, which has revolutionized cancer treatment, largely relies on the immune system’s recognition of neopeptides, degradation products of altered proteins specific to cancer cells presented on their surface. In particula... ver más

30/09/2028

WEIZMANN

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

WEIZMANN INSTITUTE OF SCIENCE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-04-18

ERC-2022-ADG: ERC ADVANCED GRANTS Scope:Objectives

I+D

Cerrada hace 2 años

0% 100% 100%

1 Participantes

WEIZMANN

2.50M€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

MIMIC Molecular mimicry as a key parameter shaping T cell immunity 2M€ Cerrado

NeoIDC Neoantigen Identification with Dendritic Cell Reprogramming 150K€ Cerrado

INCEPTOR Investigate the mode of action ofInvestigate the mode of act... 192K€ Cerrado

ImmunoChip Nano-assisted digitalizing of cancer phenotyping for immunot... 2M€ Cerrado

CAN-IT-BARRIERS Disruption of systemic and microenvironmental barriers to i... 3M€ Cerrado

PhosPepPres Improving Peptide-Based Anti-Cancer Vaccines with Phosphatas... 150K€ Cerrado

Duración del proyecto: 65 meses Fecha Inicio: 2023-04-18
Fecha Fin: 2028-09-30

Líder del proyecto

WEIZMANN INSTITUTE OF SCIENCE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Descripción del proyecto Immunotherapy, which has revolutionized cancer treatment, largely relies on the immune system’s recognition of neopeptides, degradation products of altered proteins specific to cancer cells presented on their surface. In particular, cancer vaccines targeting neopeptides have shown promising clinical results. Yet, to optimize their efficacy and broaden their application, we need to decipher the nature of the cancer peptide landscape (immunopeptidome) and delineate the neopeptide properties required to induce a potent immune response. The overarching goal of this proposal is to provide an unprecedented, thorough, multifaceted understanding of the mechanisms underlying aberrant peptide production, peptide-MHC presentation, and T-cell recognition in melanoma. We will do so by pursuing three key avenues: Systematic interrogation of the cancer immunopeptidome to identify novel canonical and non-canonical cancer antigens and quantify their presentation (Aim 1). Comprehensive functional assessment of the intrinsic qualities of actionable antigens by quantitatively charting the immunopeptidome in-vivo, while considering peptide presentation levels, clonality and cross-presentation; and delineating how these neoantigen qualities impact the immune response (Aim 2). Establish controlled in-vivo models to tease apart neoantigen qualities for the establishment of rational cancer vaccine modalities (Aim 3). In this effort, we will draw upon our pioneering tools and advanced mapping of the cancer peptidome in melanoma, which has already revealed novel antigenic sources. Our research approach combines comprehensive quantitative immunopeptidomics, novel imaging and computational approaches, advanced functional assays and novel mouse models. Our project will provide a fresh view of melanoma-immune interactions, new research tools and pipelines, cancer-specific antigen targets for immunotherapy and, more broadly, a paradigm for addressing similarly complex questions in other cancers.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores